World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0035874626
Reproduction Date:

Title: Tofenacin  
Author: World Heritage Encyclopedia
Language: English
Subject: Cimoxatone, Octamoxin, Metralindole, Caroxazone, Benmoxin
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
  • Prescription only
CAS number
10488-36-5 (HCl)
ATC code None
Chemical data
Formula C17H21NO 
Mol. mass 255.355 g/mol

Tofenacin (INN; Elamol, Tofacine, Tofalin), or tofenacin hydrochloride (USAN), also sometimes called mono-N-desmethylorphenadrine, is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).[1][2][3] It acts as a serotonin-norepinephrine reuptake inhibitor,[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. In addition to its use as a pharmaceutical medication, tofenacin is the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.[5][6]


Tofenacin synthesis: Harms August Franciscus; Koninklijke Pharma Fab Nv; U.S. Patent 3,407,258 (1964).

According to Lednicer, a second method is to react benzhydrol with ethyl bromoacetate to form α-alkoxyester, saponify, form methylamide, then reduce with LAH.

See also


  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041.  
  2. ^ J. Buckingham (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074.  
  3. ^ Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. p. 3268.  
  4. ^ Gwynn Pennant Ellis; Geoffrey Buckle West (1 January 1978). Progress in Medicinal Chemistry. Elsevier. p. 284.  
  5. ^ Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research 4 (6): 435–40.  
  6. ^ Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry 22 (6): 246–9.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.